摘要 |
PURPOSE: A pharmaceutical composition containing tat-ret-1 fusion protein is provided to effectively prevent and treat autoimmune diseases and cancer by controlling the development of HMGB1(high-mobility group box 1). CONSTITUTION: A pharmaceutical composition for treating autoimmune diseases and cancer contains tat-ref-1 fusion protein with the sequence number 1 as an active ingredient. The Tat-ref-1 fusion protein is produced by E.coli transformant BL 21(DE3)/pTat-ref-1 transformed as a development vector. The autoimmune disease includes sepsis, Churg-Strauss syndrome, Sjogren's syndrome, Systemic lupus erythematosus, or Rheumatoid arthritis. The cancer includes breast cancer, colon cancer, melanoma, prostate cancer, lung cancer or pancreatic cancer. The amount of each dose is 0.1~10 nM per day.
|